{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:00:02Z","timestamp":1791979202624,"version":"4.4.0"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJN"],"abstract":"<jats:p>Background: A large percentage of patients with Parkinson's disease (PD) suffer from excessive daytime sleepiness (EDS). This study aims to compare the effectiveness of modafinil and methylphenidate on EDS and side effects.\r\nMethods: Fifty nine patients with PD and EDS [Epworth Sleepiness Scale (ESS) more than 9] were recruited in a double-blind placebo controlled trial. Twenty-two patients received modafinil 200 mg daily, twenty-six patients received methylphenidate 10 mg daily, and 11 patients received placebo for 6 weeks. Pittsburgh Sleep Quality Index (PSQI) and ESS were filled out at baseline and 6 weeks later.\r\nResults: There was no significant difference in demographics, PSQI, and ESS variables at baseline. The mean of ESS scores decreased significantly in modafinil (17.36 \u00b1 5.05 vs. 10.55 \u00b1 4.62, P &lt; 0.001) and methylphenidate (16.27 \u00b1 5.40 vs. 12.23 \u00b1 6.28, P &lt; 0.001) groups after 6-week trial, compared with control group (14.27 \u00b1 4.49 vs. 14.09 \u00b1 4.46, P = 0.710). The effectiveness of modafinil and methylphenidate on improving daytime sleepiness and night sleep of patients was not significantly different.\r\nConclusion: Both modafinil and methylphenidate were effective drugs in improving EDS and quality of sleep without significant difference in efficiency and side effects.<\/jats:p>","DOI":"10.18502\/cjn.v23i1.16431","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:53:19Z","timestamp":1725857599000},"source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the effectiveness  of modafinil and methylphenidate  in treatment of excessive daytime sleepiness in patients with  Parkinson\u2019s disease"],"prefix":"10.18502","author":[{"given":"Ahmad","family":"Chitsaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Amirhajloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7770","published-online":{"date-parts":[[2024,9,8]]},"container-title":["Current Journal of Neurology"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/16431\/15444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/16431\/15444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:50:28Z","timestamp":1772016628000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/view\/16431"},"secondary":[{"URL":"https:\/\/cjn.tums.ac.ir\/article_40138.html","label":"UNIVERSITY"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/cjn.v23i1.16431","relation":{},"ISSN":["2717-011X"],"issn-type":[{"value":"2717-011X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]}}}